Nuance Pharma

We Are A Specialty Care
Biopharma Company

Committed To Bringing Transformational Therapies
To Patients In China And Asia

Read More

Read More
Fit For Purpose

We Transcend Clinical Application Insights That Drive Our
Clinical Development Strategy Through A Dual Wheel Model
Of Our Integrated Commercial Platform And Late Stage
Clinical Pipeline

Read More

Read More
Specialty Care
Boutique

We Focus On Developing First-in-Class Innovative Pipeline
To Address Unmet Medical Needs In Respiratory For The
Vast Patient Community In Asia
Asia Pac Vision

We Are Passionate About Exploring APAC Business Opportunities
And Have Substantive Progress In Our Asian Expansion Strategy
Bringing Therapies That Are More Accessible To People In China And Asia

Our Area Of Focus

We Have Developed A Differentiated Matrix Of Commercial Products And Innovative Pipeline Across Respiratory, Emergency Care, Iron Deficiency Anemia, Pain Management

Highlights

Founded in 2014 by Mark Lotter, Nuance has adopted a Dual-Wheel model to build a robust pipeline of innovative products while maintaining self-sustaining commercial operations in China and across Asia.

6^PRODUCTS

COMMERCIAL
4^PIPELINE

LATE STAGE CLINICAL
200⁺

EMPLOYEES WORLDWIDE

Our Transformative Journey

2026

Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by NMPA

Read More
2025

Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China

Read More
2024

US FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD

Read More
2023

Completed dosing of First Patient in Ensifentrine China phase 3 trial for COPD

Read More
2022

Launched nasal spray Bentrio™ in Hong Kong
Licensed in allergy alleviation / virus prevention nasal spray Bentrio™ from Altamira Therapeutics

Read More
2021

Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma
Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma
Acquired Sino Health with access to 3 emergency care products and a GSP license in Zhuhai

Read More
2020

Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum
Raised US$ 181 million Series D equity funding

Read More
2019

Acquired NIFEREX Iron Polysaccharide Complex Capsules

Read More
2018

Established partnership with Aerogen Pharma on nebulizer device
Accumulatively raised US$ 80 million equity funding

Read More
2014

Mr. Mark Lotter founded Nuance Pharma in Shanghai

Read More

2026

2025

2024

2023

2022

2021

2020

2019

2018

2014

2026
2025
2024
2023
2022
2021
2020
2019
2018
2014

News

2026-01-27

Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease

CONTACT

021-32035318

info@nuancepharma.com

639, East Tower, No.1376 Nanjing West Rd, Jingan, Shanghai

Privacy Statement Sitemap